Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | ENPP3 | O14638 | 5/20 | 0.39 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.39 |
| ▸ | IGFBP5 | P24593 | 3/20 | 0.37 |
| ▸ | IGFBP3 | P17936 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 4/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.34 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20030899 | 0.82 | CHRM1 (0.54) | CHRM1 | |
| SCHEMBL20030747 | 0.80 | ENPP3 (0.40) | ENPP3ENPP1CHRM1TP53S1PR1 | |
| SCHEMBL17440138 | 0.78 | CHRM1 (0.44) | ENPP3ENPP1CHRM1TP53LMNA | |
| SCHEMBL17440139 | 0.74 | TP53 (0.45) | ENPP3ENPP1IGFBP5CHRM1TP53 | |
| SCHEMBL17450461 | 0.70 | CHRM1 (0.45) | ENPP3ENPP1CHRM1TP53S1PR1 | |
| SCHEMBL23672735 | 0.69 | CHRM1 (0.41) | CHRM1 | |
| SCHEMBL23672576 | 0.68 | NPC1 (0.43) | CHRM1S1PR1LMNA | |
| SCHEMBL23673030 | 0.68 | CHRM1 (0.50) | CHRM1 | |
| SCHEMBL23672632 | 0.68 | CHRM1 (0.44) | CHRM1 | |
| SCHEMBL23672916 | 0.68 | IRAK4 (0.37) | CHRM1MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130348-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | VANDERBILT UNIVERSITY | 2021-05-06 | — | — | US | disclosed |
| WO-2018063552-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | VANDERBILT UNIVERSITY (US) | 2018-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130348-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | CHRM1, CHRM2, CHRM4 | DHODH 4707/4885ENPP3 2036/4885ENPP1 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.